Ted Schenkelberg, MBA, MPH

Ted is General Partner at the NeuroImmune Catalyst Fund, an early-stage venture capital fund investing in transformative companies and technologies for the prevention and treatment of neurodegenerative diseases, and he has over 20 years’ experience in vaccine R&D and human immunology.

Ted is a Managing Partner of Next Frontier Advisors (NFA), a consultancy firm at the nexus of human immunology, vaccine/immunothera-peutic R&D, and AI, working across industry and philanthropy. At NFA, Ted catalyzed the creation of the Alzheimer's Vaccine Initiative, which is bringing together leading academic centers to address the core scientific challenges of Alzheimer's vaccines. Previously Ted served as co-founder, Chief Strategy Officer and COO of the Human Immunome Project (formerly called the Human Vaccines Project) a non-profit R&D consortium focused on decoding the human immune system and creating AI models of human immunity to accelerate vaccine and therapeutic development, which included industry partners such as Moderna, GSK and Pfizer. 

Previously, Ted served as an R&D Director at IAVI, a global NGO that raised over $1 billion towards advanced vaccine R&D. At IAVI Ted played a key role in the creation of various global vaccine R&D consortia. Early in his career, Ted served as an Equity Analyst (Health and Tech) and member of the Investment Committee at Carnegie Capital, a private asset management firm with over $1 billion under management and administration.  

Ted has served on various nonprofit and for profit boards in the health and biotech space. He has an MBA in Finance from University of Chicago Booth School of Business, an MPH from the Johns Hopkins Bloomberg School of Public Health, and a BA from Grinnell College. Ted also served as a Visiting Scientist at the Harvard T.H. Chan School of Public Health.